Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) and Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and Aurinia Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.28 billion	8.28	-$288.28 million	($12.89)	-35.69
Aurinia Pharmaceuticals	$283.05 million	7.81	$287.20 million	$2.29	7.25

Aurinia Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Madrigal Pharmaceuticals and Aurinia Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	2	15	0	2.78
Aurinia Pharmaceuticals	0	3	2	1	2.67

Madrigal Pharmaceuticals presently has a consensus price target of $699.20, indicating a potential upside of 52.00%. Aurinia Pharmaceuticals has a consensus price target of $17.67, indicating a potential upside of 6.36%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Summary

Aurinia Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.